Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.
Myovant is developing innovative medicines that hold promise to improve people’s lives.
17 Jun 2022
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
3 Jun 2022
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
2 Jun 2022
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.